Observed Signal · Sep 16, 2026 · Conference Presentation · Source: PR Newswire: Advertising & Marketing · Impact: 2/5 · Sentiment: Positive
Cumulus Neuroscience Presents CNS Trial Data at ISCTM 2026
Cumulus Neuroscience presented three posters at the ISCTM 2026 Autumn Conference in Philadelphia, showcasing interim data on its NeuLogiq platform. The studies demonstrated high patient adherence and usability for remote multimodal brain monitoring in borderline personality disorder (BPD) and therapy-resistant depression. Additionally, a two-minute digital cognitive task (Symbol Swap) performed comparably to established clinical benchmarks for Alzheimer's trial pre-enrichment. The findings suggest that frequent digital measurement is feasible and acceptable, potentially enabling shorter, less burdensome CNS trials without compromising sensitivity. Cumulus Neuroscience developed the NeuLogiq platform in collaboration with 10 top biopharma companies to facilitate decentralized clinical trials.
The news is relevant to AdTech due to its focus on digital measurement platforms in clinical trials, but it is not directly applicable to advertising or marketing technologies.
Track Real-Time Clinical Trials Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Cumulus Neuroscience presented three posters at the ISCTM 2026 Autumn Conference in Philadelphia.
- Interim data from a BPD study showed mean adherence above 85% for cognitive and EEG sessions, with median mood adherence around 90%.
- In a therapy-resistant depression study, 98.7% of in-clinic and 90.5% of at-home sessions were completed.
- The Symbol Swap task discriminated between Alzheimer's, MCI, and control groups in about two minutes, comparable to longer clinical benchmarks.
- Cumulus Neuroscience's NeuLogiq platform was developed with 10 top biopharma companies.
- Final results from the depression study are expected in Q3 2027.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
SIBIONICS and PharmaSens Explore Automated Insulin Delivery at EASD 2026
At the EASD 2026 congress in Milan, SIBIONICS presented its vision for the future of diabetes care under the theme "See More, Act Earlier," featuring exhibits on glucose, ketone, and combined monitoring, multi-modal sensing, and broader biosensor applications. The company also held an industry symposium on new technologies shaping diabetes care. Central to the discussions was the niia signature, a research device co-developed with PharmaSens that combines continuous glucose monitoring, insulin delivery, and an automated glucose control algorithm. Early findings from the SMART02 feasibility study showed that insulin delivery near the sensor caused only rare and transient interference, with full signal recovery about 20 minutes after bolus administration. The device, still in early prototype stage, is not approved for sale in any market. The collaboration aims to simplify automated insulin delivery by integrating multiple functions into a single wearable device.
BioBrain launches AI-native OS for market research
BioBrain has introduced an AI-native operating system designed to unify market research workflows—connecting quantitative research, qualitative analysis and web intelligence. The platform automates tasks across survey programming, sample operations, quality control, data cleaning, coding, analysis and reporting, while retaining human oversight. BioBrain claims up to 4x faster project delivery, survey programming up to 80% faster, and rapid qualitative processing via its InstaQual™ capability. The company says its web-intelligence uses an RRR (Recency, Relevance, Resonance) framework to filter high-value consumer signals, and offers access to representative B2B and B2C audiences across 50+ countries.
MintNeuro raises $5M for neural device chips
MintNeuro, an Imperial College London spinout, has raised $5 million in a funding round led by Odyssey Ventures, with participation from 33East, JSK Investments, Alumni Ventures, and returning investors. The company develops specialized semiconductors for neural devices, including brain-computer interfaces (BCIs), neuromodulation systems, and wearables. The new capital will be used to scale engineering and commercial teams, bring products to market, support customer adoption, and expand into the US market. MintNeuro has already delivered working silicon and has partnerships with Motif Neurotech and Amber Therapeutics, including a multi-year commercial chip supply agreement with Motif. The company aims to become the foundational semiconductor platform for the global neurotechnology industry.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.